SK bioscience has submitted a Clinical Trial Application (CTA) to South Africa's health regulator, SAHPRA, for a Phase 1b clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE